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a  b  s  t  r  a  c  t
Breast  cancer  is  the  most  common  cancer  form  in women  and  it has  been  extensively  studied  on  the
molecular  level.  Male  breast  cancer  (MBC),  on the  other  hand,  is  rare and  has not  been  thoroughly  inves-
tigated  in  terms  of transcriptional  proﬁles  or genomic  aberrations.  Most  of our  understanding  of  MBC  has
therefore  been  extrapolated  from  knowledge  of  female  breast  cancer.  Although  differences  in  addition
to similarities  with  female  breast  cancer  have  been  reported,  the  same  prognostic  and  predictive  mark-
ers  are  used  to  determine  optimal  management  strategies  for both  men  and  women  diagnosed  with
breast  cancer.  This  review  is focused  on prognosis  for  MBC patients,  prognostic  and  predictive  factors
and  molecular  subgrouping;  comparisons  are  made  with female  breast  cancer.  Information  was collected
from  relevant  literature  on  both  male  and female  breast  cancer  from  the  MEDLINE  database  between  1992
and  2014.
MBC is a heterogeneous  disease,  and  on  the molecular  level  many  differences  compared  to female  breast
cancer  have  recently  been  revealed.  Two  distinct  subgroups  of  MBC,  luminal  M1  and luminal  M2,  have
been identiﬁed  which  differ  from  the well-established  intrinsic  subtypes  of  breast  cancer  in  women.  These
novel  subgroups  of breast  cancer  therefore  appear  unique  to  MBC.  Furthermore,  several  studies  report
inferior  survival  for men  diagnosed  with  breast  cancer  compared  to women.  New  promising  prognostic
biomarkers  for MBC  (e.g.  NAT1)  deserving  further  attention  are  reviewed.  Further  prospective  studies
aimed  at  validating  the  novel  subgroups  and  recently  proposed  biomarkers  for  MBC  are  warranted  to
provide  the  basis  for optimal  patient  management  in this  era  of  personalized  medicine.
This  article  is  part  of a  Directed  Issue  entitled:  Rare  Cancers.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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. Introduction
Male breast cancer (MBC) is similar to breast cancer in women
n some aspects; for instance invasive ductal carcinoma is the most
ommon histological type (Fentiman et al., 2006; Korde et al., 2010),
nd it is often detected as a painless subareolar lump and may  also
nvolve nipple retraction or bleeding from the nipple (Giordano,
005; Ruddy and Winer, 2013). However, there are also many dif-
erences between breast cancers occurring in men  vs. women. Most
otably, breast cancer is much less common in men  (only 1% of all
reast cancers in the US (Siegel et al., 2013) and 0.5% in the Nordic
ountries (Engholm et al., 2013) occur in men), men  are often older
t diagnosis (67 vs. 62 years) (Giordano et al., 2002), their tumors
re more often hormone receptor positive (estrogen receptor (ER)
ositivity 91–95% vs. 76–78% and progesterone receptor (PR) posi-
ivity 80–81% vs. 67%, in men  and women, respectively) (Anderson
t al., 2010; Giordano et al., 2002; Nilsson et al., 2013b). Lobular car-
inoma is also much less common in men  (Giordano et al., 2002;
eigelt et al., 2010).
A family history of breast and ovarian cancer is a risk factor for
eveloping breast cancer in men, as in women; germline BRCA2
utations have been reported in 4–14% of MBC  patients, while
RCA1 mutations are less frequent, occurring in up to 4% of MBC
atients (Basham et al., 2001; Chodick et al., 2008; Couch et al.,
996; Ding et al., 2010; Friedman et al., 1997; Ottini et al., 2008;
truewing et al., 1999). BRCA1 and BRCA2 mutations confer an esti-
ated increased lifetime risk of developing breast cancer of 1–6%
nd ∼7%, respectively (Levy-Lahad and Friedman, 2007; Liede et al.,
004; Tai et al., 2007), while the general lifetime risk in the male
opulation is 0.1% (Engholm et al., 2013; Liede et al., 2004). Among
ther germline mutations that confer a moderately increased risk
f developing breast cancer in women, data for men  are mixed for
ALB2, CHEK2 and CYP17 (Blanco et al., 2011; Ding et al., 2010;
alchetti et al., 2007; kConFab et al., 2009; Ohayon et al., 2004;
ilvestri et al., 2010b; Syrjäkoski et al., 2003; Wasielewski et al.,
008; Young et al., 1999), while no increased risks have been found
or BRIP1 and RAD51 C with regards to MBC  (Silvestri et al., 2010a,
011). A large genome-wide association study of MBC  has identi-
ed TOX3 and RAD51B to confer increased risks for MBC, the RAD51B
ocus being a novel breast cancer susceptibility locus (Orr et al.,
012). Other risk factors for men  are associated with changes in
he hormonal balance of estrogen to androgen, such as in Kline-
elter’s syndrome (resulting in a 50-fold increased risk) (Brinton
t al., 2009; Hultborn et al., 1997), testicular abnormalities that
esult in testosterone deﬁciency (Brinton et al., 2009; Thomas et al.,
992), liver diseases (Sørensen et al., 1998), obesity (Brinton et al.,
008, 2009; Ewertz et al., 2001; Hsing et al., 1998) and exoge-
ous estrogen exposure (Medras et al., 2006; Thellenberg et al.,
003).
The number of breast cancer diagnoses among women  has
ncreased over the past decades (Ly et al., 2012; Socialstyrelsen,
012), while the incidence of MBC  has not risen in most countries
Ly et al., 2012), with the exception of a slight increase that has been
eported from England, Scotland, Australia and the USA (Giordano
t al., 2004; Speirs and Shaaban, 2008; Stang and Thomssen, 2008;
hite et al., 2011).
Research into the etiology and tumor biological properties of
BC  has been limited due to the rareness of the disease, and
ost data are derived from retrospective studies covering long . . . . .  .  . . . . . . .  . . . . .  .  . . . . . . . .  .  . . .  . . .  . . . . . . .  . . .  .  .  . . . .  .  . . .  .  .  .  . . . .  . . .  . . .  .  . . . . . 534
time periods and geographical regions. Therefore, MBC  patients
are currently being managed according to guidelines developed for
female patients; there is however currently insufﬁcient knowledge
to determine whether this is the most optimal strategy.
2. Prognosis of male breast cancer
The outcome of men  diagnosed with breast cancer compared
to women is currently debated. Many recent studies have shown
worse survival for MBC  patients (Chen et al., 2013; Gnerlich et al.,
2012; Greif et al., 2012; Miao et al., 2011; Nilsson et al., 2011; Scott-
Conner et al., 1999; Yildirim and Berberog˘lu, 1998); however this
difference becomes less apparent when the cohorts are stratiﬁed
on various prognostic factors (Giordano et al., 2004; Miao et al.,
2011; Shaaban et al., 2012). Table 1 summarizes the largest studies
comparing survival for male and female breast cancer patients to
date (Chen et al., 2013; Giordano et al., 2004; Gnerlich et al., 2012;
Greif et al., 2012; Miao et al., 2011; Nilsson et al., 2011; Scott-Conner
et al., 1999; Shaaban et al., 2012).
Many of the studies in Table 1 cover long periods of time,
are based on small sample sizes, and/or include patients from
many different hospitals and sometimes also countries. This is an
unavoidable consequence of the rarity of the disease and limits
the interpretation of the results. Moreover, when comparing over-
all survival (OS) between the genders, it needs to be taken into
consideration that women  have a slightly longer expected survival
than men; e.g. in Sweden, life expectancy is 84 years for women
and 80 years for men  (Centralbyrån, 2014). Nevertheless, Table 1
includes two  single center studies: one from Sweden including
99 MBC  patients and one from China with 150 MBC  patients, and
both these studies showed inferior outcome for MBC  patients (Chen
et al., 2013; Nilsson et al., 2011). The Swedish study matched on age
and date of diagnosis, and contrary to what has been anticipated
from the literature, found no differences in disease stage between
the genders. Despite this, a signiﬁcantly worse relative survival was
observed for men  (Nilsson et al., 2011). The Chinese study matched
patients for age, date of diagnosis and stage, and found a signif-
icantly inferior disease-free as well as OS for men  (Chen et al.,
2013). We know today that breast cancer is a very heterogeneous
disease in general and that it can be divided into comprehensive
subgroups associated with differences in response to treatment and
outcome. The question therefore arises on which factors one should
match when comparing outcome for men  vs. women diagnosed
with breast cancer. Notwithstanding, when male and female breast
cancer patients are compared on a population based level, the rela-
tive overall and breast cancer speciﬁc survival appears to be worse
for male patients (Cancerfonden, 2013; Chen et al., 2013; Greif et al.,
2012; Miao et al., 2011; Nilsson et al., 2011). For example, in Sweden
the relative 5-year OS rates for all male and all female patients
are 79.6 and 90.0%, respectively, while the corresponding relative
10-year OS rates are 67.1 and 83.5% (Cancerfonden, 2013). Further-
more, a clear trend toward increased survival rates for women with
breast cancer has been seen in Sweden (Cancerfonden, 2013) and
in the US, while only a small trend toward increased survival was
found among men  in the US (Anderson et al., 2010). Taken together,
these ﬁndings suggest that there may  be underlying differences in
tumor biology between breast cancers arising in men and women,
and that these may  affect outcome.
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3. Molecular subtyping of breast cancer
Breast cancer has been extensively studied on the transcrip-
tomic, genomic and even epigenomic levels and the development
of high throughput technologies and bioinformatics tools have
made it possible to investigate large numbers of tumors. Much has
been learned over the past decades regarding how to subclassify
breast cancer into comprehensive subgroups with different bio-
logical and clinical features, leading to a paradigm shift in how
we understand and study breast cancer in women and how breast
cancer patients are managed. In 2000, Perou et al. published the
ﬁrst paper suggesting a subclassiﬁcation of breast cancer by using
gene expression proﬁles, coining the concept of intrinsic subtypes
(Perou et al., 2000). These groups have been further reﬁned and
validated by them and others over the years. The ﬁve main intrin-
sic subtypes of breast cancer are (Eroles et al., 2012; Goldhirsch
et al., 2013; Hu et al., 2006; Parker et al., 2009; Sørlie et al., 2001,
2003):
• Luminal A (50–60%): The majority are ER positive, they display
low proliferation, and are considered more endocrine sensitive
than luminal B tumors.
• Luminal B (10–20%): The majority are ER positive, they are often
highly proliferative and are less endocrine responsive than lumi-
nal A tumors. Many BRCA2 mutated tumors belong to this group.
• Basal-like (10–20%): The majority are triple-negative (ER, PR and
HER2 negative) and they may express cytokeratins 5, 6 and 14.
The majority of BRCA1 mutated tumors belong to this group.
• HER2-enriched (10–15%): The majority exhibit ampliﬁcation
and/or overexpression of HER2 as well as other genes in the HER2
amplicon. An overrepresentation of ER negative tumors is found
in this group.
• Normal-like (5–10%): Genes deﬁning this group are expressed in
normal breast tissue, but this is not a well-deﬁned subgroup. It
is not clear whether tumors classiﬁed as normal-like represent
a true subtype of breast cancer, or whether they reﬂect tumors
with a high degree of normal epithelial cells.
The intrinsic subtypes have distinct clinical features, with the
basal-like and HER2 subgroups displaying the worst prognosis and
luminal A the best, while luminal B tumors have an intermediate
prognosis (Hu et al., 2006; Parker et al., 2009; Sørlie et al., 2001,
2003). Through the years, additional subgroups have been identi-
ﬁed, including the claudin-low subgroup, which is characterized by
being triple negative (negative for ER, PR and HER2). These tumors
have cancer stem cell like features, express high levels of epithelial-
to-mesenchymal transition (EMT) genes, display low expression of
luminal genes, claudins 3, 4 and 7 and express high levels of genes
expressed by lymphocytes (Herschkowitz et al., 2007; Prat et al.,
2010). During recent years it has further been shown that triple neg-
ative breast cancers are a heterogeneous group, and Lehmann et al.
(2011) identiﬁed as many as six subgroups of the triple-negative
tumors.
Female breast cancers have also been subclassiﬁed based on
DNA copy number and DNA methylation levels. These subgroups
correlate to some extent with the transcriptionally derived intrin-
sic subtypes, but have also further reﬁned the classiﬁcation of
breast cancer and contributed to the understanding of the biology
of the intrinsic subtypes (Chin et al., 2006; Dedeurwaerder et al.,
2011; Fridlyand et al., 2006; Holm et al., 2010; Jönsson et al., 2010;
Russnes et al., 2010). The Cancer Genome Atlas (TCGA) network
combined ﬁve types of genomic data (DNA copy number arrays,
DNA methylation arrays, exome sequencing, mRNA arrays, miRNA
sequencing and reverse-phase protein arrays) to identify subgroups
of breast cancer. They identiﬁed four subgroups, which corre-
lated well with the intrinsic subtypes; moreover the integrated
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nformation across platforms helped to further explain the under-
ying biology of the intrinsic subtypes (Koboldt et al., 2012). Curtis
t al. also combined genomic and transciptomic data, thereby iden-
ifying ten distinct subgroups associated with different clinical
utcomes and candidate driver genes, further reﬁning the classi-
cation of breast cancer (Dawson et al., 2013; METABRIC Group,
012).
.1. Surrogate IHC based deﬁnitions of the intrinsic breast cancer
ubtypes
Due to costs and tissue handling requirements associated with
ranscriptional proﬁling, a need to develop assays more applicable
o large numbers of tumors has led to the translation of the intrin-
ic subtypes to an immunohistochemistry (IHC) based surrogate
ssay. An approximation of the classiﬁcation into the intrinsic gene
xpression derived subtypes can thereby be accomplished based
n expression levels of a small number of proteins. This allows for
nalysis of parafﬁn embedded archival tumor material to a fraction
f the cost associated with mRNA based subtyping. Several deﬁni-
ions have been proposed, and the most commonly used surrogate
HC based deﬁnitions for classifying breast cancers into the intrinsic
ubtypes are (Goldhirsch et al., 2013; Kaufmann and Pusztai, 2011;
rat et al., 2013):
Luminal A:
• Deﬁnition I: ER and/or PR positive, HER2 negative.
• Deﬁnition II: ER and/or PR positive, HER2 negative, low Ki67.
• Deﬁnition III: ER positive, PR positive, HER2 negative, low Ki67.
Luminal B:
• Deﬁnition I: ER and/or PR positive, HER2 positive.
• Deﬁnition II: ER and/or PR positive, HER2 positive and/or high
Ki67.
• Deﬁnition III: ER positive, HER2 positive and/or high Ki67
and/or PR negative.
Triple-negative (Basal-like): ER, PR and HER2 negative, and some-
times also CK5/6 and/or EGFR and/or CK14 positive.
HER2-enriched: ER and/or PR negative, HER2 positive.
Deﬁnition II improved the distinction between luminal A and
uminal B tumors by incorporating the proliferation marker Ki67.
owever, during the years there have been many concerns about
he considerable lack of reproducibility across laboratories for the
ssessment of Ki67. Ki67 has proven difﬁcult to evaluate; however
 recent trial showed that Ki67 scoring is reproducible when tis-
ue microarray (TMA) sections were stained with a standardized
ethod, a common scoring method was used and the evaluators
ad been trained using a web based calibration tool (Polley et al.,
013). This report however highlights the difﬁculties associated
ith comparing non-standardized Ki67 results across different lab-
ratories or studies. Deﬁnition III is the most recent, and it has
urther improved the distinction between luminal A and luminal
 tumors by also requiring luminal A tumors to be PR positive
Prat et al., 2013), and it was included in the 2013 guidelines
rom the St Gallen consensus conference (Goldhirsch et al., 2013).
his is of importance for treatment decision making, as patients
ith luminal B tumors are generally recommended chemotherapy
ased regimens, while patients with luminal A tumors are generally
ot (Goldhirsch et al., 2013). Although the degree of concordance
etween the IHC derived subgroups and the intrinsic transcrip-
ional subtypes is relatively high at 75–90% (Kaufmann and Pusztai,
011), the St Gallen consensus recommended whenever possible to
se gene expression based subtyping over the surrogate IHC based
pproach for decisions regarding chemotherapy for patients with
uminal tumors (Goldhirsch et al., 2013).chemistry & Cell Biology 53 (2014) 526–535 529
3.2. IHC based classiﬁcation of MBC
A number of independent research groups have attempted to
subclassify MBCs into the intrinsic subtypes using the same IHC
based deﬁnitions as those described above for female breast cancer.
A summary of the results is shown in Table 2, with a recent large
study of female breast cancer included as reference (Blows et al.,
2010; Ge et al., 2009; Kornegoor et al., 2011; Nilsson et al., 2013a;
Shaaban et al., 2012; Yu et al., 2013).
In common between these reports, the majority of the MBC
tumors were classiﬁed as luminal A (60–98%), the subgroup of
female breast cancer associated with the best survival. When def-
inition I was  used to classify female breast cancers, 71% were
classiﬁed as luminal A (Blows et al., 2010), while gene expression
based classiﬁcation generally results in about 50–60% luminal A
tumors (Eroles et al., 2012). These data suggest that distinguish-
ing between luminal A and B in general is problematic when using
deﬁnition I. While Ki67 is applied in deﬁnitions II and III for separat-
ing luminal A from luminal B tumors, studies without standardized
protocols for scoring of Ki67 are difﬁcult to compare as discussed
above. Nevertheless, when studies using deﬁnition I were com-
pared, MBCs were more often classiﬁed as luminal A compared to
female breast cancers (83–98% vs. 71%) (Blows et al., 2010; Ge et al.,
2009; Nilsson et al., 2013a; Shaaban et al., 2012), with the exception
of the Chinese study which reported very different distributions of
the subgroups compared to the other studies (Yu et al., 2013). Fewer
basal-like (0–2% vs. 16%) and HER2 enriched (0% vs. 6%) MBC  tumors
were reported in these studies than what is seen in female breast
cancer. These subgroups are associated with the worst prognosis
among women (Blows et al., 2010; Ge et al., 2009; Nilsson et al.,
2013a; Shaaban et al., 2012). The report by Ye and colleagues is
therefore surprising in light of the inferior relative OS as well as
breast cancer speciﬁc survival (BCSS) among male patients com-
pared to females (Cancerfonden, 2013; Chen et al., 2013; Greif et al.,
2012; Miao et al., 2011; Nilsson et al., 2011). Based on the studies
reported to date, it appears as though a subgroup of aggressive MBC
is not captured when the traditional IHC proxy markers are used
for classiﬁcation. These data further suggest that men and women
diagnosed with breast cancer of the same IHC based subtype do
not have similar outcomes and therefore most likely respond dif-
ferently to standard therapies. Taken together, this indicates the
need for additional biomarkers to successfully identify and classify
all cases of aggressive MBC, and furthermore that they may  require
different treatment strategies.
4. Global proﬁling of MBC
In contrast to female breast cancer, MBC  is not well studied
on the genomic and epigenomic levels and there have only been
a few array based studies investigating DNA copy number aberra-
tions (Johansson et al., 2011; Tommasi et al., 2010), gene expression
proﬁles (Callari et al., 2010; Johansson et al., 2012) and microRNA
proﬁles (Fassan et al., 2009; Lehmann et al., 2010), summarized
in Table 3. All these global array based studies revealed that MBC,
like breast cancer in females, is a heterogeneous disease. Moreover,
many differences between male and female breast cancers, hid-
den behind the overall similarities, were discovered (Callari et al.,
2010; Fassan et al., 2009; Johansson et al., 2011, 2012; Lehmann
et al., 2010; Tommasi et al., 2010). When we combined the gene
expression data (Johansson et al., 2012) with the array compara-
tive genomic hybridization (aCGH) data (Johansson et al., 2011) to
identify potential candidate driver genes of male and female breast
cancer, the landscapes of candidate drivers were vastly different
between the genders, with only two  candidate drivers in common,
TAF4 and CD164 (Johansson et al., 2013). MBC thereby appears to
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Table  2
Classiﬁcation of male breast cancer into IHC based subgroups.
Study
(Number of patients)
Luminal A Luminal B Triple-negative (basal-like) HER2-enriched
N  (%) N (%) N (%) N (%)
Male breast cancer
Nilsson et al. (2013a,b)a
(183)
160 (87%) 21 (11%) 2 (1%) 0 (0%)
Yu  et al. (2013)a
(68)
41 (60%) 17 (25%) 4 (6%) 6 (9%)
Shaaban et al. (2012)a
(203)
199 (98%) 0 (0%) 4 (2%) 0 (0%)
Kornegoor et al.
(2011)b
(129)
98 (76%) 27 (21%) 4 (3%) 0 (0%)
Ge et al. (2009)a
(42)
35 (83%) 7 (17%) 0 (0%) 0 (0%)
Female  breast cancer
Blows et al. (2010)a
(10,159)
7243 (71%) 639 (6%) 1645 (16%) 632 (6%)
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iffer from female breast cancer on the molecular level, potentially
uggesting different mechanisms of tumorigenesis.
.1. MBC  miRNAs and epigenetics
In both microRNA studies mentioned above, MBCs were com-
ared with (non-malignant) gynecomastia samples; Fassan et al.
dentiﬁed 43 microRNAs and Lehman et al. identiﬁed 54 microRNAs
hat were differentially expressed. Furthermore, when the MBCs
ere compared with female breast cancers, both studies identiﬁed
everal microRNAs differentially expressed between the genders
Fassan et al., 2009; Lehmann et al., 2010). In another study, ana-
yzing RASSF1A and RAR promoter methylation status and the
xpression of miRNAs miR17, miR21, miR124, and let-7a in famil-
al breast cancers from 27 males and 29 females, miR17 and let-7
xpression was lower in breast cancers from men  than women,
hile RASSF1A was more frequently methylated in the MBCs (Pinto
t al., 2013). Hypermethylation of tumor suppressor genes has been
hown to play a key role in tumor progression in breast cancer
Baylin and Herman, 2000; Jones, 2002; Jones and Baylin, 2007).
NA methylation has not yet been studied on a global level in
BC, although Kornegoor et al. studied promoter methylation of
5 tumor suppressor genes in 108 MBC  tumors and compared
hem to 33 female breast cancer tumors. Several hypermethylated
enes were shared between the genders; however many of the
enes investigated were less frequently methylated among the
BC  tumors, notably ESR1, BRCA1 and BRCA2 (Kornegoor et al.,
012).
able 3
rray based proﬁling studies of male breast cancer.
Study
(Number of MBCs)
Type of data Platform 
Johansson et al. (2011)
(56)
aCGH BAC arrays 
Tommasi et al. (2010)
(25)
aCGH Agilent Human Genome 
Microarray Kit 44B and 4
Johansson et al. (2012)
(66)
mRNA Illumina HT12 v3 
Callari et al. (2010)
(37)
mRNA Custom made cDNA micr
Lehmann et al. (2010)
(9)
microRNA 319 mi RNAs 
Fassan et al. (2009)
(23)
microRNA Custom miRNA microarr
containing ∼1100 probes4.2. MBC  genomics
On the copy number level, two studies applying metaphase
CGH to 39 and 26 MBCs, respectively, reported that the most com-
mon  aberrations were the same in male and female breast cancers
(Rudlowski et al., 2006; Tirkkonen et al., 1999). In our aCGH studies
of MBC, based on high resolution tiling BAC arrays, we  also recog-
nized that the most common aberrations were the same in male
in female breast cancers. However, when studied in more detail,
many differences between male and female breast cancer were
revealed (Johansson et al., 2011). Tommasi et al. found that the
MBC  tumors had an overall lower frequency of copy number aber-
rations compared to female breast cancers. However, the eleven
cases of female breast cancer used in their study were all ER nega-
tive basal-like tumors, an aggressive type of breast cancer harboring
the largest number of copy number aberrations among all female
breast cancers (Jönsson et al., 2010). This makes it difﬁcult to draw
any conclusions regarding copy number differences between male
and female breast cancer in general (Tommasi et al., 2010). In con-
trast, in our study, where 56 MBC  tumors were compared to 359
FBC tumors, run on the same platform and normalized in the same
manner, we  identiﬁed more gains and fewer losses among the MBC
tumors. The MBC  tumors also harbored more whole chromosome
arm gains and fewer high-level ampliﬁcations than the FBC tumors
(Johansson et al., 2011). Furthermore, in a gene expression proﬁl-
ing study, Callari et al. reported several genes to be differentially
expressed between the genders. However, they performed a direct
comparison between male and female breast cancers even though
FBC samples Platform FBC
359 BAC arrays
CGH
4K
16 Agilent Human Genome CGH
Microarray 44B
359 Spotted oligonucleotide array
from Swegene
oarray 53 Custom made cDNA microarray
Various published studies
ay chip 10 Custom miRNA microarray chip
containing ∼1100 probes
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hey were run at different time points, making it difﬁcult to distin-
uish true ﬁndings from potential technical artifacts (Callari et al.,
010). We  reported a global gene expression proﬁling study based
n 66 MBCs with 359 female breast cancers for comparison; how-
ver they were not run on the same platform and therefore only
ndirect comparisons between the genders could be performed
Johansson et al., 2012). The results are discussed in the following
ections.
.3. Global subgrouping of MBC
Accurate subtyping of MBC  into comprehensive subgroups is
ssential for developing an appropriate therapeutic strategy. Today,
reatment decisions for male patients are based on biomarkers
eveloped for breast cancer in women, although we do not know if
hey sufﬁciently capture the heterogeneity of breast cancer arising
n men. The sub-classiﬁcation of MBC  into the IHC based sub-
roups of female breast cancer indicates that these markers do not
dequately identify the aggressive forms of MBC (Ge et al., 2009;
ilsson et al., 2013a; Shaaban et al., 2012; Yu et al., 2013). We
herefore recently sought to subclassify MBC  into different sub-
roups in an unsupervised manner using different types of genome
cale data and then compared these MBC  subgroups with the pre-
iously described intrinsic subtypes of female breast cancer. Two
ubgroups were identiﬁed both on the copy number and transcrip-
ional level, and these groups were highly correlated, indicating
undamental underlying differences (Johansson et al., 2011, 2012).
A large cohort of 359 female breast cancers, in which Jönsson
t al. had previously identiﬁed six subgroups (7q12, basal-complex,
uminal-simple, luminal-complex, ampliﬁer and mixed), was  used
s a reference dataset in our aCGH study of MBC. Four of these
ubgroups were correlated with the intrinsic, transcriptionally
erived subtypes; basal-complex with basal-like, 17q12 with HER2
nriched, luminal-complex with luminal B and luminal-simple
ith luminal A, respectively (Jönsson et al., 2010). In an attempt
o subclassify the MBC  tumors in our cohort, we performed hierar-
hical clustering based on 133 commonly aberrant genomic regions
dentiﬁed among the female breast cancers (Johansson et al., 2011).
he clustering revealed two subgroups with signiﬁcantly differ-
nt aberrant copy number levels, which we named male-complex
80% of tumors) and male-simple (20% of tumors), respectively. The
ale-simple subgroup appeared to be comprised of less aggres-
ive tumors, as they were found to have a lower overall fraction
f the genome altered, lower S-phase fractions and the tumors
ere smaller. This subgroup was remarkably different from the
reviously described six subgroups of breast cancer, and seemed to
epresent a new subgroup of breast cancer occurring only in males.
umors in the more aggressive subgroup of MBC, male-complex,
ere overall similar to the luminal-complex subgroup of female
reast cancer. When the groups were studied in more detail, how-
ver, differences in whole chromosome aberrations and common
berrant regions were revealed (Johansson et al., 2011).
Gene expression proﬁling is a common method used for deﬁning
he phenotypes of various tumor types at the transcriptional level;
he most extensively studied tumor type in this context is breast
ancer (Hu et al., 2006; Parker et al., 2009; Sørlie et al., 2001, 2003).
ince MBCs make up a very small fraction of all breast cancers,
hey have not previously gained much attention in this context.
o date, we are the only group who has focused speciﬁcally on
ubclassifying MBC  tumors using global gene expression proﬁles.
ierarchical clustering was performed on 66 MBCs using the top
ost varying genes across the dataset; two subgroups, luminal M170% of tumors) and luminal M2  (30% of tumors), were thereby
dentiﬁed. The stability of these subgroups was  validated by hier-
rchical clustering of the tumors on co-clustering frequencies from
0,000 bootstrapped datasets, and furthermore the subgroups werechemistry & Cell Biology 53 (2014) 526–535 531
also validated (Johansson et al., 2012) in an external dataset of
MBC  (Callari et al., 2010). Due to the limited sample size no fur-
ther subdivision was possible, but it is possible that additional
subgroups of MBC  may  exist. Importantly, when the novel MBC
subgroups were compared with each of the intrinsic subtypes of
FBC, no resemblance to any subtype was  observed. Classiﬁcation of
MBC  tumors into (female) intrinsic breast cancer subtypes accord-
ing to the gene expression centroids published by Hu et al. (2006)
resulted in >50% of the MBC  tumors being unclassiﬁed. Conversely,
>60% of the female breast cancers in the reference dataset were not
classiﬁable into the MBC  (luminal M1/M2) subgroups. Recognizing
that >90% of MBC  tumors are ER positive, we therefore also classi-
ﬁed the MBCs using only genes for ER positive female breast cancers
(i.e. luminal A/B); still 36% remained unclassiﬁed (Johansson et al.,
2012). To further study the biological differences between the new
MBC  subgroups and the intrinsic subtypes of female breast cancer,
we applied seven gene expression modules representing key bio-
logical processes involved in breast cancer tumorigenesis (Desmedt
et al., 2008) to the datasets. The luminal M2  subgroup of MBC
demonstrated higher scores for the immune response and ER mod-
ules, while luminal M1  MBC  tumors displayed higher scores for
the tumor invasion and metastasis, proliferation and HER2 mod-
ules, indicating that MBCs of the luminal M1  subgroup display
more aggressive features than other MBC  tumors. When comparing
the patterns of the module scores across the intrinsic subtypes of
female breast cancer and the MBC  subgroups, neither of the MBC
subgroups displayed patterns resembling any of the intrinsic sub-
types (Fig. 1). Instead, the MBC  subgroups shared different features
with different intrinsic subtypes. These ﬁndings suggest that the
two MBC  subgroups appear to be unique in terms of underlying
biology and may  occur only in males (Johansson et al., 2012). In
order to ﬁrmly establish the relation between male and female
breast cancer, and to establish the distribution of subtypes, global
unsupervised transcriptional proﬁling should be applied to a large
cohort representing the whole spectrum of both male and female
breast cancers, enabling direct comparisons.
5. ER activity in MBC
An unexpected ﬁnding from the gene expression proﬁling study
was that the more aggressive MBC  tumors of the luminal M1  sub-
group displayed a very low score for the ER module, despite the
majority of the tumors being ER positive by IHC (Fig. 1). By compar-
ison, both luminal subtypes of female breast cancer within which
the vast majority of the tumors are ER positive, displayed equally
high module scores for ER, while the basal-like subtype, mainly
harboring ER negative tumors, had the lowest score for ER. Hence,
even if luminal M1  MBC  tumors are ER positive they appear to share
some features with ER negative female breast cancers. Given the
data above, this may  indicate that luminal M1 MBC  tumors might
not have an active ER pathway, leading to the question whether
these patients respond to endocrine treatment in the same way
as women with an ER positive tumor (Johansson et al., 2012).
Two other reports on hormone receptors in MBC  have indicated
different hormonal dependencies in male and female breast can-
cer (Shaaban et al., 2012; Weber-Chappuis et al., 1996). Shaaban
et al. studied 251 male and 263 female breast cancers matched on
age, grade, and lymph node status. They investigated the hormone
receptors ER,  ER1, -2, -5, PR, PRA, PRB and AR by IHC on a TMA
and hierarchically clustered the male and female tumors separately
based on the expression of these proteins. Among female breast
cancers, the PR isoforms and ER clustered together, while the PR
isoforms formed a separate cluster and ER clustered together with
the ER isoforms and AR in MBC  (Shaaban et al., 2012). Weber-
Chappuis et al. studied parafﬁn-embedded tumor material from 66
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Fig. 1. Gene expression modules associated with key biological processes. The module scores of gene expression modules representing key biological processes involved in
breast  cancer tumorigenesis (Desmedt et al., 2008) in the two gene expression subgroups of MBC  (A), in the intrinsic subgroups of female breast cancer (B), and in the MBC
validation dataset (C), respectively. Proliferation (Wilcoxon test, P = 0.064), HER2 (Wilcoxon test, P = 0.0057), tumor invasion and metastasis (Wilcoxon test, P = 1.0 × 10–5),
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ER  (Wilcoxon test, P = 1.3 × 10–8) and immune response (Wilcoxon test, P = 0.16) d
BC  (A). The ANOVA test was used to calculate P-values (B).
eprinted with permission from Breast Cancer Research (Johansson et al., 2012).
ale and 190 female breast cancer patients by IHC, stained for hor-
one receptors and antigens under estrogen and androgen control.
hey found that although a larger fraction of the male tumors were
R positive compared to the female tumors, they were only weekly
ssociated with antigens under estrogen control and more often
ositive for antigens under androgen control, while the opposite
as true for female breast cancer (Weber-Chappuis et al., 1996).
urthermore, in a large genome-wide association study of MBC,
o association was found to the rs2981582 SNP in the ﬁbroblast
rowth factor receptor 2 (FGFR2) gene (Orr et al., 2012) known to
ave the strongest known association with ER positive breast can-
er in women (García-Closas et al., 2008). Also, in the investigation
f candidate driver genes in male vs. female breast cancer, GATA3
as identiﬁed as one of the top candidate drivers among all female
reast cancers as well as within the luminal A and luminal B sub-
ypes, while it was not identiﬁed as a candidate driver for MBC.
AP2K4, which is also highly connected to ER positive breast cancer
n women was however identiﬁed as a candidate driver also among
BCs (Johansson et al., 2013). This further supports the notion that
ot all ER positive MBC  tumors behave in the same way as ER posi-
ive tumors in women, but rather seem to share features with both
R positive and ER negative female breast cancer.ed a signiﬁcant or borderline signiﬁcant difference between the two subgroups of
6. Prognostic and predictive biomarkers in MBC
Many prognostic and predictive factors been investigated in
breast cancer, and some are established and used in the clinic
today to guide treatment decisions. The current St Gallen con-
sensus guidelines recommend age at diagnosis, tumor size, lymph
node status, presence of distant metastases, histological classiﬁca-
tion, Nottingham histological grade (NHG), ER, PR, HER2 and Ki67
to be used in the clinical setting (Goldhirsch et al., 2013). These
factors are not as a well established for MBC  and have only been
evaluated in a small number of retrospective trials; there is thus
little evidence that they provide the same prognostic and predic-
tive information as for women. In fact, many of the studies have
shown contradicting results: some studies have found high NHG
to be an independent prognostic factor for poor prognosis (Cutuli
et al., 2010), while others have not (Giordano et al., 2004; Johansson
et al., 2012). This is also true for Ki67, where some studies found it to
have no prognostic value (Kanthan et al., 2010; Nilsson et al., 2013b;
Wang-Rodriguez et al., 2002), while another study found Ki67 to
be prognostic (Rayson et al., 1998). As mentioned above, however,
the difﬁculties associated with evaluation of Ki67 limit the abil-
ity to draw any ﬁrm conclusions based on non-standardized Ki67
 of Biochemistry & Cell Biology 53 (2014) 526–535 533
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0 1 2 3 4 5 6 7 8 9 11 13 15
Time (years)
No. at Risk
THY1-negative   24 20 18 14 12 8 5 2 2 2 1 1 1 1 1 1
THY1-positive   29 25 20 17 13 11 6 6 4 3 2 1 0 0 0 0
Fig. 2. Kaplan–Meier survival analysis. Distant metastasis free survival of the 66
male breast cancer patients stratiﬁed by THY1 gene expression. The numbers below
the  plots indicate the number of patients at risk in each group at the given time
points.
Reprinted with permission from PLoS ONE (Johansson et al., 2013).
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No. at Risk
NAT1-positive   66 56 44 38 33 25
NAT1-negative 78 63 56 47 35 20
Fig. 3. Kaplan–Meier survival analysis. Distant metastasis free survival of the 220
male breast cancer patients included in the TMA  stratiﬁed NAT1 expression. TheI. Johansson et al. / The International Journal
esults (Polley et al., 2013). Both Ki67 and NHG are strongly asso-
iated with proliferation and proliferation is highly prognostic in
emale breast cancer, particularly in patients with ER positive can-
ers. One would therefore expect it to be prognostic even for men
iagnosed with breast cancer, among whom >90% of the tumors are
R positive. Other markers have been used to study proliferation in
emale breast cancer, including the cyclins (Agarwal et al., 2009;
lintman et al., 2013; Michalides et al., 2002; Niméus-Malmström
t al., 2010). We  assessed cyclins A, B and D1 in a cohort of 197 MBC
umors, and while Ki67 was not found to be prognostic, cyclins A
nd B were prognostic for poor prognosis and cyclin D1 predicted a
etter outcome (Nilsson et al., 2013b). Cyclin D1 was  also found to
redict better outcome in MBC  in two other studies (Kanthan et al.,
010; Rayson et al., 1998). The study by Kanthan et al. also reported
ther cell cycle protein markers in a cohort of 75 MBCs, and found
hat c-myc positive tumors were also linked with favorable out-
ome while overexpression of p21, p57, and PCNA was  associated
ith worse outcome. No correlation with outcome was however
ound for Ki67, p27 or p16 (Kanthan et al., 2010). Notably, Lacle
t al. did not ﬁnd mitotic index, one of the three components of
HG, to be prognostic in a series of 151 MBCs. The expression of
cl2 was also investigated, which neither alone nor in combination
ith mitotic index was  prognostic (Lacle et al., 2013). In contrast,
he combination has been proven to be of strong prognostic value in
emale breast cancer (Abdel-Fatah et al., 2010). Furthermore, one
f the seven transcriptional modules representing key biological
rocesses in breast cancer tumorigenesis was involved in prolif-
ration (Desmedt et al., 2008), and the more aggressive luminal
1 MBC  tumors showed a higher score for this module compared
o the luminal M2  MBCs. No differences in Ki67 or cyclin A lev-
ls were however observed between the subgroups (Johansson
t al., 2012). SPAG5,  which regulates a gene module involved in the
itotic checkpoint control and progression, was identiﬁed as a can-
idate driver gene in MBC. However, no difference in survival was
bserved between MBCs positive and negative for SPAG5,  respec-
ively (Johansson et al., 2013). SPAG5 has on the other hand been
hown to be prognostic in ER positive but not in ER negative female
reast cancers (Abdel-Fatah et al., 2012; Johansson et al., 2013).
nother interesting candidate driver identiﬁed in MBC  tumors was
HY1, which regulates a gene network involved in invasion and is
elated to EMT. Of interest, men  with THY1 positive breast cancers
ad signiﬁcantly inferior survival compared to those with negative
umors (Fig. 2) (Johansson et al., 2013). It may  therefore be possible
hat processes other than proliferation are more important for the
ggressive behavior of a subset of MBCs. Another protein recently
ound to be prognostic for disease-speciﬁc survival in sporadic but
ot familial MBC  was HIF1A (Deb et al., 2014).
With the aim of identifying novel prognostic biomarkers of rele-
ance in MBC, we assessed the genes that varied the most between
he luminal M1  and M2  MBC  tumors in our transcriptional pro-
ling study. One of these genes, NAT1, was followed up on the
rotein level using a TMA  of 220 MBC  tumors. There was  a high
egree of correlation between the protein and mRNA levels of
AT1, and furthermore luminal M1 tumors displayed low levels of
AT1 on both mRNA and protein levels. Men  with NAT1 negative
reast tumors had signiﬁcantly inferior survival compared to those
ith NAT1 positive tumors, a ﬁnding that remained signiﬁcant in
he multivariate setting (Fig. 3) (Johansson et al., 2012). High lev-
ls of NAT1 have been shown to predict response to tamoxifen in
omen with ER positive breast cancer. NAT1 is a xenobiotic metab-
lizing enzyme that may  be involved in metabolizing tamoxifen,
hereby potentially contributing to tamoxifen activation (Bièche
t al., 2004). This may  further indicate that although their tumors
re ER positive, men  with luminal M1  breast cancer may  not
espond in the same way to tamoxifen as women with ER positive
reast cancer.numbers below the plots indicate the number of patients at risk in each group at
the  given time points.
Reprinted with permission from Breast Cancer Research (Johansson et al., 2012).
7. Concluding remarks
Due to the fact that the relative OS and BCSS for men  is inferior
compared to women, and since recent studies suggest that the
prognostic factors used in clinical practice today do not accu-
rately capture the aggressive MBCs, new biomarkers for MBC  are
needed. As such, NAT1 and THY1 are two  new promising candidate
biomarkers for MBC  that deserve further attention. Stratiﬁcation of
MBC into molecularly based subgroups has revealed two subgroups
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hat differ both on the copy number and transcriptional levels from
emale breast cancers and thereby seem to constitute two new
reast cancer subgroups occurring only in males. Furthermore, the
ore aggressive MBC  subgroup, luminal M1,  might not have an
ctive ER pathway despite the majority of cases being ER positive.
BCs clearly constitute a molecularly and clinically heterogeneous
roup of malignancies, which differ from breast cancer in women.
nderstanding this diversity is essential to be able to improve the
rognosis for MBC  patients and to optimize treatment strategies.
urther research into MBC  is required to optimize management
trategies and to improve survival. The rarity of the disease
ecessitates international collaborations to increase sample sizes
n future studies. To this end, an international EORTC sponsored
onsortium has been established to study MBC  (ClinicalTrials.gov
CT01101425); it includes a retrospective part, collecting clinical
ata and archival tissue for translational investigations, as well as
 prospective clinical part.
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